SillaJen, Transgene fall with latest oncolytic virus setback

The failure of Pexa-Vec from Transgene and SillaJen in a Phase III study is the latest blow to the oncolytic virus field, but it may say less about the modality as a whole than about the virus' specific construct and trial design.

SillaJen Inc. (KOSDAQ:215600), which holds North American rights to Pexa-Vec, will likely feel the brunt of the impact as Pexa-Vec is its only clinical candidate. Its shares lost W13,350 (30%) to W31,200 on Friday...